[go: up one dir, main page]

EA201791095A1 - Способ лечения рака - Google Patents

Способ лечения рака

Info

Publication number
EA201791095A1
EA201791095A1 EA201791095A EA201791095A EA201791095A1 EA 201791095 A1 EA201791095 A1 EA 201791095A1 EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A EA201791095 A EA 201791095A EA 201791095 A1 EA201791095 A1 EA 201791095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment method
cancer treatment
inhibitor
ezh2
methods
Prior art date
Application number
EA201791095A
Other languages
English (en)
Inventor
Хайке Кайльхак
Бретт Труитт
Юта Сузуки
Цукаса Мурасе
Футоси Сиката
Original Assignee
Эпизайм, Инк.
ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., ЭИСАИ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. filed Critical Эпизайм, Инк.
Publication of EA201791095A1 publication Critical patent/EA201791095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим ингибитор(ы) гистонметилтрансферазы EZH2 человека, и способам терапии рака с применением ингибитора(ов) EZH2.
EA201791095A 2014-11-17 2015-11-17 Способ лечения рака EA201791095A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
EA201791095A1 true EA201791095A1 (ru) 2017-10-31

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791095A EA201791095A1 (ru) 2014-11-17 2015-11-17 Способ лечения рака

Country Status (21)

Country Link
US (3) US10786511B2 (ru)
EP (2) EP4272742A1 (ru)
JP (3) JP6829684B2 (ru)
KR (3) KR102644844B1 (ru)
CN (2) CN116650500A (ru)
AU (3) AU2015350108B2 (ru)
BR (1) BR112017010166A2 (ru)
CA (1) CA2967664A1 (ru)
DK (1) DK3220916T3 (ru)
EA (1) EA201791095A1 (ru)
ES (1) ES2947819T3 (ru)
FI (1) FI3220916T3 (ru)
HU (1) HUE062159T2 (ru)
IL (3) IL296080B2 (ru)
LT (1) LT3220916T (ru)
MX (2) MX383484B (ru)
PL (1) PL3220916T3 (ru)
PT (1) PT3220916T (ru)
SG (1) SG11201703806XA (ru)
SI (1) SI3220916T1 (ru)
WO (1) WO2016081523A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
ES2750199T3 (es) 2012-10-15 2020-03-25 Epizyme Inc Métodos para tratar el cáncer
EP3076977B1 (en) 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
ES2948442T3 (es) 2014-06-17 2023-09-12 Epizyme Inc Inhibidores de EZH2 para el tratamiento de linfoma
CN116650500A (zh) 2014-11-17 2023-08-29 Epizyme股份有限公司 治疗癌症的方法
US10456407B2 (en) 2015-04-20 2019-10-29 Epizyme, Inc. Combination therapy for treating cancer
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
JP2023509385A (ja) * 2019-12-20 2023-03-08 エピザイム インコーポレイテッド Ｅｚｈ２阻害剤の結晶性ヒドロブロミド塩、その調製及びがんの治療に有用な医薬組成物
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
DK2614369T3 (en) * 2010-09-10 2016-05-02 Epizyme Inc METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
PL2825161T3 (pl) 2012-03-12 2019-06-28 Epizyme, Inc. Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
IL282732B2 (en) * 2012-04-13 2023-04-01 Eisai R&D Man Co Ltd Salt form of human histone methyltransferase inhibitor 2ezh
CN104768555B (zh) 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
JP6461803B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
ES2750199T3 (es) * 2012-10-15 2020-03-25 Epizyme Inc Métodos para tratar el cáncer
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
SG11201602269QA (en) 2013-10-16 2016-04-28 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
EP3076977B1 (en) 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
ES2948442T3 (es) * 2014-06-17 2023-09-12 Epizyme Inc Inhibidores de EZH2 para el tratamiento de linfoma
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX383635B (es) 2014-10-16 2025-03-14 Epizyme Inc Método para tratar el cáncer.
CN116650500A (zh) 2014-11-17 2023-08-29 Epizyme股份有限公司 治疗癌症的方法
AU2016275051A1 (en) * 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Also Published As

Publication number Publication date
CN107249591B (zh) 2024-01-30
SG11201703806XA (en) 2017-06-29
JP2023062189A (ja) 2023-05-02
CN116650500A (zh) 2023-08-29
EP3220916A4 (en) 2018-07-11
FI3220916T3 (fi) 2023-06-19
IL296080B2 (en) 2023-12-01
US10786511B2 (en) 2020-09-29
KR102338802B1 (ko) 2021-12-14
IL296080B1 (en) 2023-08-01
KR20240035908A (ko) 2024-03-18
PT3220916T (pt) 2023-06-26
JP6829684B2 (ja) 2021-02-10
MX2017006089A (es) 2017-12-11
KR102644844B1 (ko) 2024-03-07
EP3220916B1 (en) 2023-04-19
WO2016081523A1 (en) 2016-05-26
HUE062159T2 (hu) 2023-10-28
AU2021204706A1 (en) 2021-07-29
IL296080A (en) 2022-11-01
ES2947819T3 (es) 2023-08-21
EP3220916A1 (en) 2017-09-27
NZ768247A (en) 2024-05-31
US12168014B2 (en) 2024-12-17
EP4272742A1 (en) 2023-11-08
JP2017537899A (ja) 2017-12-21
KR20170103768A (ko) 2017-09-13
AU2024201171A1 (en) 2024-03-14
LT3220916T (lt) 2023-07-25
JP2021073241A (ja) 2021-05-13
CN107249591A (zh) 2017-10-13
PL3220916T3 (pl) 2023-08-14
AU2015350108A1 (en) 2017-05-25
DK3220916T3 (da) 2023-06-26
JP7485810B2 (ja) 2024-05-16
CA2967664A1 (en) 2016-05-26
KR20210156840A (ko) 2021-12-27
US20250064822A1 (en) 2025-02-27
BR112017010166A2 (pt) 2018-02-14
US20210060030A1 (en) 2021-03-04
SI3220916T1 (sl) 2023-09-29
IL252182A0 (en) 2017-07-31
NZ731696A (en) 2024-03-22
US20170360797A1 (en) 2017-12-21
AU2015350108B2 (en) 2021-04-08
AU2021204706B2 (en) 2023-11-23
IL304252A (en) 2023-09-01
IL252182B2 (en) 2023-02-01
MX2021006734A (es) 2021-07-02
MX383484B (es) 2025-03-11
IL252182B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
EA201791095A1 (ru) Способ лечения рака
EA201890567A1 (ru) Способ лечения рака
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201591599A1 (ru) Ингибиторы ido
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
ZA201807438B (en) Methods of treating ocular conditions
ZA201703467B (en) Methods of treating ocular conditions
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
EA201691896A1 (ru) Соединения и способы их применения
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX383460B (es) Derivados peptidicos novedosos y sus usos.